ALSO KNOWN AS HUNTINGTON’S CHOREA · HD
A physician-led, laboratory-verified treatment programme designed to slow functional decline, reduce chorea severity and support cognitive stability — tailored to the individual biology, disease stage and clinical profile of each Huntington’s patient.
Request Medical ConsultationAbout the Condition
Huntington’s disease (HD) is a hereditary neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the HTT gene on chromosome 4. This mutation produces a toxic form of the huntingtin protein, which progressively damages neurons — particularly in the caudate nucleus and putamen of the basal ganglia.
The disease manifests as a triad of motor dysfunction (chorea, dystonia, bradykinesia), cognitive decline (executive function impairment, slowed processing, eventual dementia) and psychiatric disturbance (depression, irritability, apathy, obsessive-compulsive behaviours).
HD affects approximately 5–10 people per 100,000 in populations of European descent. There is currently no disease-modifying pharmacological treatment. Standard care focuses on symptom management — which is where our programme provides a structured biological intervention targeting the mechanisms of neuronal loss.
Adult-onset Huntington’s Disease
The typical form, accounting for approximately 90% of cases. Symptom onset usually occurs between ages 30 and 50, beginning with subtle motor or psychiatric changes that progress over 15–20 years. CAG repeat length is typically 40–55. Chorea is the dominant early motor feature, with cognitive and psychiatric symptoms developing in parallel.
Juvenile Huntington’s Disease (Westphal Variant)
Accounts for approximately 5–10% of cases, with onset before age 20. Associated with longer CAG repeats (typically >60). Presents differently from adult-onset HD: rigidity and bradykinesia predominate over chorea, seizures are common, and cognitive decline is more rapid. Progression is generally faster than adult-onset forms.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates genetic confirmation, disease stage, motor and cognitive status, psychiatric profile and overall clinical condition.
We do not offer a cure for Huntington’s disease. Our programme targets the biological mechanisms driving neuronal degeneration — with the clinical objective of slowing functional decline, reducing symptom severity and preserving autonomy for as long as possible.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2015 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
38
Huntington’s disease patients treated
72%
demonstrated measurable functional stabilisation within 3–6 months
61%
showed reduction in chorea severity assessed by motor UHDRS
54%
reported improvement in cognitive task performance and daily executive function
+2.1 pts
average UHDRS Total Functional Capacity score change in the first 6 months
66%
maintained sustained functional stability — follow-up to 2.5 years
Reduction in involuntary choreiform movements
64%
Improved gait stability and balance during daily activity
57%
Enhanced executive function and task completion
49%
Reduction in psychiatric symptom severity (depression, irritability)
55%
Improved swallowing coordination and speech clarity
46%
2–6 weeks
Initial functional response
3–6 months
Clinically meaningful change
2+ years under continued monitoring
Functional stabilisation phase
Important: Outcomes depend on disease stage, CAG repeat length, baseline UHDRS scores, age of onset and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“She can eat at the table with us again. My wife’s chorea had gotten so severe she couldn’t hold a cup without spilling. After treatment in Warsaw, the involuntary movements calmed down noticeably. She’s less frustrated, more herself. Her neurologist in London confirmed the improvement is objective.”
Patient’s husband
Huntington’s disease · United Kingdom
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our Huntington’s disease programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient’s biological profile, disease stage, and clinical priorities.
No surgery required
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
Important in Huntington’s disease, where involuntary movements and psychiatric medication interactions can complicate anaesthesia management.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient’s own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets the underlying biology, not just symptoms
Rather than masking chorea or managing psychiatric symptoms alone, our protocol targets neuroinflammation, mitochondrial dysfunction and striatal degeneration — the biological drivers of HD progression.
Complements existing medication
Our programme is compatible with tetrabenazine, antipsychotics and other current HD medications. Patients do not need to discontinue existing treatment before commencing our protocol.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient’s location anywhere in the world. For patients where long-distance travel is difficult due to motor or psychiatric symptoms, this removes a major barrier to accessing care.
What It Is
MSCs are multipotent regenerative cells with proven immunomodulatory and neuroprotective properties. They are among the most extensively studied cell types in regenerative medicine and have demonstrated safety across thousands of clinical applications worldwide.
How It Is Done
Cells are collected from the patient’s own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are then expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Huntington’s Disease
In Huntington’s disease, mutant huntingtin protein triggers chronic neuroinflammation and progressive death of striatal neurons. MSCs address this directly by suppressing the inflammatory cascade in the basal ganglia, secreting neurotrophic factors that support surviving neurons and creating a more protective microenvironment that slows the rate of neuronal loss.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, disease stage, biological markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current UHDRS status, genetic confirmation, medical history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme. Where clinically appropriate, our medical board may approve a travelling treatment programme — our medical team flies directly to the patient.
Structured rehabilitation sessions with our specialist, adapted to your current motor function, cognitive status and psychiatric needs. Available at our clinic or remotely coordinated with your local medical team.
Your dedicated coordinator monitors functional status, provides clinical guidance and adjusts recommendations based on your recovery data. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of Huntington’s disease patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient’s status has changed — including psychiatric destabilisation or severe dysphagia — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rehabilitation specialist
monitors motor function, cognitive status and psychiatric well-being
Personalised rehabilitation programme
adapted to current functional capacity, chorea severity and cognitive profile
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Our approach is based on the principle that biological regeneration requires time, monitoring and adjustment. The period following treatment is as medically important as the treatment itself.
Get Started
If you or someone you love has been diagnosed with Huntington’s disease, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, current stage and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
